AstraZeneca and Amgen Submit BLA to US FDA for Tezepelumab to Treat Severe Asthma
Shots:
- The submission is based on PATHFINDER clinical program including P-III NAVIGATOR that involves assessing Tezepelumab + SOC vs PBO + SOC in 1061 adults (18–80yrs.) & adolescents (12–17yrs.) with severe and uncontrolled asthma
- The study demonstrated 56% reduction in AAER @52wks. in the overall population. The study also met 1EPs in the subgroup of patients i.e. 41% reduction in low levels of eosinophils <300 cells/microliter- improvements in lung function measurements- asthma control & health related QoL
- Tezepelumab is the only biologic to reduce AAER consistently in a broad population of severe asthma patients irrespective of the baseline eosinophil counts across P-II & P-III studies
Ref: PRNewswire | Image: Amgen
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com